Substituted piperazines as KRAS G12C inhibitors

US12083121B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• John Gordon Allen · Newbury Park, US
• Brian Alan LANMAN · Calabasas, US
• Jian Chen · Camarillo, US
• Anthony B. Reed · Newbury Park, US
• Victor J. Cee · Thousand Oaks, US
• Longbin Liu · Thousand Oaks, US
• Patricia Lopez · Calabasas, US
• Ryan Wurz · Newbury Park, US
• Thomas Nguyen · Newbury Park, US
• Shon Booker · Thousand Oaks, US
• Jennifer R. Allen · Newbury Park, US
• Margaret Chu-Moyer · Brookline, US
• Albert Amegadzie · Moorpark, US
• Ning Chen · Thousand Oaks, US
• Clifford GOODMAN · Thousand Oaks, US
• Jonathan D. Low · Thousand Oaks, US
• Vu Van Ma · Simi Valley, US
• Ana Elena Minatti · Santa Monica, US
• Nobuko Nishimura · Calabasas, US
• Alexander J. Pickrell · Westlake Village, US
• Hui-Ling Wang · Thousand Oaks, US
• Youngsook Shin · Emeryville, US
• Aaron C. Siegmund · Ventura, US
• Kevin Yang · San Gabriel, US
• Nuria A. Tamayo · Newbury Park, US
• Mary Walton · Pacifica, US
• Qiufen Xue · Thousand Oaks, US

Key dates

• Filing date: Jan 19, 2022
• Grant date: Sep 10, 2024
• Expiry date: Feb 18, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.